Protocol-Specific Research Support (PSRS) Innovative clinical research, especially that tied to UMGCC basic research and involving pilot or pre Phase I, or Phase I investigator-initiated trials testing clinical interventions with a candidate agent or device for the diagnosis, prevention, detection, or treatment of cancer may be eligible for Protocol Specific Research Support (PSRS). Such support will underwrite research coordinator activities and data management functions. Data from such research protocols can be used to support later phase activities with these interventions, or as a basis for acquiring funding from other sources to continue the piloted activities. This critical early support provided by PSRS, is necessary to move such trials forward, especially because per patient costs are not reimbursed. PSRS, utilizing recently revised (2008) guidelines from the National Cancer Institute (NCI) for its use, will support research coordinators and data managers at UMGCC to facilitate these innovative clinical investigation efforts. Trials supported by PSRS will be approved for such funding only after meeting additional criteria as judged by the Clinical Research Committee. The trials will be assigned a priority scale for funding based on how the protocol is, respectively, significant and innovative in promoting the development of a novel cancer diagnosis, treatment, imaging, or prevention strategy. Additional criteria include evidence that the proposed trial possesses correlative science that will be critically enabled as a result of PSRS funding, with translational collaborators and assays in place, and the use of PSRS funding will allow the development of independent or future funding vehicles for the research strategy. Five of 22 recently (CY2009) approved investigator-initiated trials in UMGCC's portfolio potentially qualify for the up to 1 year of research nurse and data manager support in accord with the new PSRS guidelines limiting the type of use and period of applicable PSRS funding. This support will give UMGCC the flexibility to advance the cause of high-priority, innovative, early phase clinical trials. These trials will have no or at best partial industry support, excluding per-patient costs. Ideally, PSRS-supported studies would flow from investigator initiated clinical research, or would be the logical consequence of an alliance between basic scientists at UMGCC and clinicians who are suitable for addressing a translational science goal that is not incorporated into other grant-supported trials of NCI or other funding agencies.
PSRS is instrumental in launching pilot or Phase I investigator-initiated trials and will help bridge support for these trials as other support is being defined or allow completion in its own right of pilot trials. This activity is essential in the role of UMGCC as a catalyst of innovative investigator-initiated proposals tied to science to reach the clinic in a rapid fashion, in support of the defining mission of the NCI Cancer Center Support Grant.
|NygÃ¥rd, Lotte; Vogelius, Ivan R; Fischer, Barbara M et al. (2016) Early lesion-specific (18)F-FDG PET response to chemotherapy predicts time to lesion progression in locally advanced non-small cell lung cancer. Radiother Oncol 118:460-4|
|Fox, Jennifer M; Moynihan, James R; Mott, Bryan T et al. (2016) Artemisinin-derived dimer ART-838 potently inhibited human acute leukemias, persisted in vivo, and synergized with antileukemic drugs. Oncotarget 7:7268-79|
|Joseph, Ann Mary; Srivastava, Ratika; Zabaleta, Jovanny et al. (2016) Cross-talk between 4-1BB and TLR1-TLR2 Signaling in CD8+ T Cells Regulates TLR2's Costimulatory Effects. Cancer Immunol Res 4:708-16|
|Zandberg, Dan P; Liu, Sandy; Goloubeva, Olga et al. (2016) Oropharyngeal cancer as a driver of racial outcome disparities in squamous cell carcinoma of the head and neck: 10-year experience at the University of Maryland Greenebaum Cancer Center. Head Neck 38:564-72|
|Doshi, Kshama A; Trotta, Rossana; Natarajan, Karthika et al. (2016) Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress. Oncotarget 7:48280-48295|
|Ambulos Jr, Nicholas P; Schumaker, Lisa M; Mathias, Trevor J et al. (2016) Next-Generation Sequencing-Based HPV Genotyping Assay Validated in Formalin-Fixed, Paraffin-Embedded Oropharyngeal and Cervical Cancer Specimens. J Biomol Tech 27:46-52|
|Temburnikar, Kartik W; Ross, Christina R; Wilson, Gerald M et al. (2015) Antiproliferative activities of halogenated pyrrolo[3,2-d]pyrimidines. Bioorg Med Chem 23:4354-63|
|Kochel, Tyler J; Fulton, Amy M (2015) Multiple drug resistance-associated protein 4 (MRP4), prostaglandin transporter (PGT), and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) as determinants of PGE2 levels in cancer. Prostaglandins Other Lipid Mediat 116-117:99-103|
|Rasmussen, Jacob H; Vogelius, Ivan R; Aznar, Marianne C et al. (2015) Spatio-temporal stability of pre-treatment 18F-Fludeoxyglucose uptake in head and neck squamous cell carcinomas sufficient for dose painting. Acta Oncol 54:1416-22|
|Shih, Yu-Huan; Zhang, Yuji; Ding, Yonghe et al. (2015) Cardiac transcriptome and dilated cardiomyopathy genes in zebrafish. Circ Cardiovasc Genet 8:261-9|
Showing the most recent 10 out of 207 publications